Pfizer (NYSE:PFE) reported positive topline Phase 2b results for its once monthly GLP-1 obesity candidate PF-3944. The drug, acquired through Pfizer's purchase of Metsera, showed significant weight ...

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Pfizer Inc. (NYSE:PFE) is one of the best large cap stocks to buy under $50. On February 3, Pfizer announced positive topline ...

Global pharmaceutical company Pfizer (NYSE:PFE) announced better-than-expected revenue in Q4 CY2025, but sales fell by 1.2% ...

Pharmaceutical operations remain central to large-cap healthcare discussions Balance sheet positioning frames institutional comparisons Broader sentiment reflects themes seen in s&p 500 chart Pfizer ...

Management indicated full year revenue is expected to align with broader market expectations Non GAAP earnings per share ...

Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share ...

Analysts expect Pfizer’s revenue to decrease approximately 5% to around $16.95 billion, while adjusted earnings per share are projected to fall 9.5% to 57 cents compared to 63 cents in the same period ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer Inc. (NYSE:PFE) ranks among the stocks with the lowest forward PE ratios. On January 23, Goldman Sachs reaffirmed its ...

Pfizer beat analysts’ revenue expectations by 0.6% last quarter, reporting revenues of $16.65 billion, down 5.9% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS ...

Pfizer (NYSE: PFE) posted fourth-quarter 2025 revenue of about $18 billion, down 1% from the year-ago quarter, and adjusted ...